Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.
Laura Joiner, PharmD, BCOP
Advertisement
Articles by Laura Joiner, PharmD, BCOP
Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.
Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.
Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
House Votes to Extend ACA Subsidies, Eyes Turn to Senate
2
5 Key Health Care Changes During Trump’s First Year Back in Office
3
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
4
Redefining Oncology Through the Academic-Community Dyad Model
5
